These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 15645969)

  • 41. [Long-term complete remission in primary plasma cell leukemia after treatment with VAD chemotherapy and tandem autologous peripheral blood stem cell transplantation].
    Iino M; Nakajima A; Shindo H
    Gan To Kagaku Ryoho; 2008 Dec; 35(13):2441-3. PubMed ID: 19098420
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Plasma cell leukemia: another piece of the puzzle.
    Musto P; Wäsch R
    Haematologica; 2023 Apr; 108(4):941-944. PubMed ID: 35770536
    [No Abstract]   [Full Text] [Related]  

  • 43. Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia.
    Chang H; Qi X; Yeung J; Reece D; Xu W; Patterson B
    Leuk Res; 2009 Feb; 33(2):259-62. PubMed ID: 18676019
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A double punch for plasma cell leukemia.
    Kaiser M
    Haematologica; 2023 Apr; 108(4):939-940. PubMed ID: 35770535
    [No Abstract]   [Full Text] [Related]  

  • 45. Plasma cell leukemia.
    Gertz MA; Buadi FK
    Haematologica; 2010 May; 95(5):705-7. PubMed ID: 20442443
    [No Abstract]   [Full Text] [Related]  

  • 46. Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia.
    Kim SJ; Kim J; Cho Y; Seo BK; Kim BS
    Jpn J Clin Oncol; 2007 May; 37(5):382-4. PubMed ID: 17538191
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Plasma cell leukemia induced to complete remission with negative minimal residual disease by qualitative PCR analysis after hyper-CVAD and high-dose melphalan followed by autologous peripheral blood stem cell transplantation].
    Hosono N; Yamauchi T; Nakamura T; Yamashita T; Ueda T
    Gan To Kagaku Ryoho; 2008 Mar; 35(3):533-7. PubMed ID: 18347412
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Plasmacytoid dendritic cell leukaemia/lymphoma: towards a well defined entity?
    Garnache-Ottou F; Feuillard J; Saas P
    Br J Haematol; 2007 Feb; 136(4):539-48. PubMed ID: 17367408
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rouleaux formation.
    Abramson N
    Blood; 2006 Jun; 107(11):4205. PubMed ID: 16739263
    [No Abstract]   [Full Text] [Related]  

  • 50. Efficacy and safety of bortezomib in patients with plasma cell leukemia.
    Musto P; Rossini F; Gay F; Pitini V; Guglielmelli T; D'Arena G; Ferrara F; Filardi N; Guariglia R; Palumbo A; ; ;
    Cancer; 2007 Jun; 109(11):2285-90. PubMed ID: 17469169
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular cytogenetic aberrations in 21 Chinese patients with plasma cell leukemia.
    Xu W; Li JY; Fan L; Chen LJ; Qiu HR; Qiu HX; Lu H
    Int J Lab Hematol; 2009 Jun; 31(3):338-43. PubMed ID: 18284415
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hyperammonaemic encephalopathy in plasma cell leukaemia.
    Shenoy C
    Intern Med J; 2007 Nov; 37(11):784-6. PubMed ID: 17908093
    [No Abstract]   [Full Text] [Related]  

  • 53. Poor clinical outcome of elderly patients with primary plasma cell leukemia treated with novel agents: real-world experience.
    Saburi M; Sakata M; Takata H; Miyazaki Y; Kawano K; Sasaki H; Abe M; Kohno K; Soga Y; Nagamatsu K; Ono K; Nakayama T; Ohtsuka E
    Leuk Lymphoma; 2022 Nov; 63(11):2691-2695. PubMed ID: 35687847
    [No Abstract]   [Full Text] [Related]  

  • 54. Frequent upregulation of MYC in plasma cell leukemia.
    Chiecchio L; Dagrada GP; White HE; Towsend MR; Protheroe RK; Cheung KL; Stockley DM; Orchard KH; Cross NC; Harrison CJ; Ross FM;
    Genes Chromosomes Cancer; 2009 Jul; 48(7):624-36. PubMed ID: 19396865
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of solitary plasmacytoma in the internal auditory canal and inner ear after allogeneic hematopoietic stem cell transplantation for plasma cell leukemia.
    Masuda M; Inoue Y; Tanosaki R; Kanzaki S; Ogawa K
    Jpn J Clin Oncol; 2007 Sep; 37(9):701-3. PubMed ID: 17673474
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bortezomib in multiple myeloma: treatment and retreatment. A single center experience.
    Warzocha K; Kraj M; Pogłód R; Kwaśniak B
    Acta Pol Pharm; 2008; 65(6):753-6. PubMed ID: 19172860
    [No Abstract]   [Full Text] [Related]  

  • 57. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma.
    Mattioli M; Agnelli L; Fabris S; Baldini L; Morabito F; Bicciato S; Verdelli D; Intini D; Nobili L; Cro L; Pruneri G; Callea V; Stelitano C; Maiolo AT; Lombardi L; Neri A
    Oncogene; 2005 Apr; 24(15):2461-73. PubMed ID: 15735737
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Thalidomide-induced pneumonitis in a patient with plasma cell leukemia: No recurrence with subsequent lenalidomide therapy.
    Pretz J; Medeiros BC
    Am J Hematol; 2009 Oct; 84(10):698-9. PubMed ID: 19691102
    [No Abstract]   [Full Text] [Related]  

  • 59. Successful treatment of primary plasma cell leukaemia by allogeneic stem cell transplantation from haploidentical sibling.
    Nonami A; Miyamoto T; Kuroiwa M; Kunisaki Y; Kamezaki K; Takenaka K; Harada N; Teshima T; Harada M; Nagafuji K
    Jpn J Clin Oncol; 2007 Dec; 37(12):969-72. PubMed ID: 18055567
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia.
    Jaskiewicz AD; Herrington JD; Wong L
    Pharmacotherapy; 2005 Dec; 25(12):1820-5. PubMed ID: 16305302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.